Please login to the form below
AZD3293
This page shows the latest AZD3293 news and features for those working in and with pharma, biotech and healthcare.
Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat
The demise of the BACE1 inhibitor – also known as AZD3293/LY3314814 – adds to the litany of failures among drugs intended to treat Alzheimer’s, and specifically those trying to slow down
Latest news
-
Biogen rises on more positive data for Alzheimer's candidate
compounds. Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
-
Lilly taps AstraZeneca for another anti-amyloid drug
The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running
-
Lilly sinks as solanezumab fails again in Alzheimer's
AZD3293. Ricks has previously suggested that if EXPEDITION3 was a bust then the expensive, 2, 500-patient prodromal trial will probably be abandoned.
-
AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug
AstraZeneca and Eli Lilly's collaboration in Alzheimer's disease continues to make progress, as their AZD3293 drug is granted a fast-track review by the US FDA. ... AZ and Lilly are already carrying out one phase II/III placebo-controlled trial of AZD3293
-
Eisai and Biogen plan phase III trials for Alzheimer's drug
others. Merck has already started phase III trials of its MK-8931 candidate, while Lilly and AZ recently did likewise with AZD3293.
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2016
Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior Account Executive, London, Medical Communications
-
Excellent package
-
Senior Medical Writer
-
Great salary and benefits
-
Senior Account Manager
-
Negotiable
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
-
Medical Writers
-
Competitive Salary and Benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Consumer Health Account Director
-
Circa £60, 000 Gym and More
-
Associate Director
-
£75, 000-90, 000
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
-
Account Director
-
£48, 000 - £60, 000
Subscribe to our email news alerts
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
- World Diabetes Day: Interaction and impact of diabetes on mental health
- For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
Quick links
Infographics
